CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Olaparib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02898207
NCT02898207Phase 1Completed
CompareCT.gov

A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

National Cancer Institute (NCI)·interventional·Posted Sep 13, 2016·Updated Apr 26, 2023

In Brief

A Phase 1 clinical trial evaluating Olaparib and Onalespib for Metastatic High Grade Fallopian Tube Serous Adenocarcinoma and 18 related conditions. Completed, enrolled 28 participants across 8 sites.

Detailed Summary

This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back (recurrent). Olaparib and onalespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Breast Carcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Serous Adenocarcinoma, Refractory Primary Peritoneal Serous Adenocarcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable High Grade Fallopian Tube Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Primary Peritoneal Serous Adenocarcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 13, 2016
Enrollment StartMay 19, 2017
Primary CompletionJul 29, 2020
Study CompletionJan 14, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.8 years ago

Interventions

Olaparibdrug

Given PO

Onalespibdrug

Given IV